<SEC-DOCUMENT>0001193125-13-201827.txt : 20130506
<SEC-HEADER>0001193125-13-201827.hdr.sgml : 20130506
<ACCEPTANCE-DATETIME>20130506165911
ACCESSION NUMBER:		0001193125-13-201827
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20130502
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20130506
DATE AS OF CHANGE:		20130506

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARCA biopharma, Inc.
		CENTRAL INDEX KEY:			0000907654
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				363855489
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-22873
		FILM NUMBER:		13816847

	BUSINESS ADDRESS:	
		STREET 1:		8001 ARISTA PLACE
		STREET 2:		SUITE 200
		CITY:			BROOMFIELD
		STATE:			CO
		ZIP:			80021
		BUSINESS PHONE:		720-940-2200

	MAIL ADDRESS:	
		STREET 1:		8001 ARISTA PLACE
		STREET 2:		SUITE 200
		CITY:			BROOMFIELD
		STATE:			CO
		ZIP:			80021

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NUVELO INC
		DATE OF NAME CHANGE:	20030203

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HYSEQ INC
		DATE OF NAME CHANGE:	19970610
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d532538d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>WASHINGTON, D.C. 20549 </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>FORM 8-K
</B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>CURRENT REPORT </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Pursuant to Section&nbsp;13 or 15(d) of the </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Securities Exchange Act of
1934 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Date of Report (Date of Earliest Event Reported): May&nbsp;6, 2013 (May 2, 2013) </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>ARCA biopharma, Inc. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(Exact Name of Registrant as Specified in Charter) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Delaware</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>000-22873</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>36-3855489</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(State or Other Jurisdiction</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>of Incorporation)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Commission&nbsp;File Number)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(I.R.S. Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Identification No.)</B></FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>8001 Arista Place, Suite 200, Broomfield, CO 80021 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Address of Principal Executive Offices) (Zip Code) </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(720) 940-2200 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Registrant&#146;s Telephone Number, Including Area Code)
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Not Applicable </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>(Former Name or Former Address, if Changed Since Last Report) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:10px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain
Officers; Compensatory Arrangements of Certain Officers. </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">On May&nbsp;6, 2013, ARCA issued a press release announcing that its Board member
Burton E. Sobel had died on May&nbsp;2, 2013. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Section&nbsp;9 &#151; Financial Statements and Exhibits </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;9.01. Financial
Statements and Exhibits. </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) Exhibits. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD WIDTH="86%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:55pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit&nbsp;Number</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000;width:39pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release titled &#147;ARCA ANNOUNCES DEATH OF BOARD MEMBER BURTON E. SOBEL, PREEMINENT PHYSICIAN SCIENTIST AND ACADEMIC LEADER,&#148; dated May 6, 2013.</FONT></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SIGNATURES </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dated: May&nbsp;6, 2013 </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="bottom" COLSPAN="3" NOWRAP> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARCA biopharma, Inc.</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(Registrant)</FONT></P></TD></TR>


<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;/s/ Christopher D. Ozeroff</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name: Christopher D. Ozeroff</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title: SVP &amp; General Counsel</FONT></TD></TR>
</TABLE></DIV>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>EXHIBIT INDEX </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:39pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit&nbsp;No.</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000;width:39pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release titled &#147;ARCA ANNOUNCES DEATH OF BOARD MEMBER BURTON E. SOBEL, PREEMINENT PHYSICIAN SCIENTIST AND ACADEMIC LEADER,&#148; dated May&nbsp;6, 2013.</FONT></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d532538dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 99.1 </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right">


<IMG SRC="g532538g90l26.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Contact: </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Derek Cole </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Investor Relations Advisory Solutions </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">720.940.2163 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>derek.cole@arcabiopharma.com
</U></FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARCA ANNOUNCES DEATH OF BOARD MEMBER BURTON E. SOBEL, </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>PREEMINENT PHYSICIAN SCIENTIST AND ACADEMIC LEADER </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Broomfield, CO, May&nbsp;6, 2013</I> &#150; ARCA biopharma, Inc. (Nasdaq: ABIO), today announced that Burton E. Sobel, 75, a member of its Board of Directors, has died. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;Burt was recognized as one of the great academic physicians of our time. He did groundbreaking work in several fields of cardiovascular medicine
including blood coagulation, which led to major advances in the treatment of heart attacks and other thromboembolic diseases, as well as seminal work on myocardial function and biochemistry in response to hemodynamic stress. Burt will be deeply
missed by his family, friends, colleagues and the many patients whose lives were greatly improved by his contributions to cardiovascular medicine.&#148; commented Michael Bristow, MD, PhD, President and CEO of ARCA. &#147;All of us at ARCA are
deeply saddened by his passing.&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Sobel was a Professor of Medicine and Biochemistry at the University of Vermont, Director of the
Cardiovascular Research Institute at the University, and former Chairman of the Department of Medicine. Previously, he had held academic and leadership positions at other major research institutions. Sobel edited major cardiovascular and medical
journals, and had over 800 manuscripts published. He was active in the pharmaceutical industry as well, and had served on several boards of directors in addition to ARCA. Sobel received numerous awards, including a Research Career Development Award
from the National Institutes of Health, a Distinguished Scientist Award from the American College of Cardiology and the Herric Award from the American Heart Association. He was a magna cum laude graduate of the Harvard Medical School. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>www.arcabiopharma.com </U></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2">### </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g532538g90l26.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g532538g90l26.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`.0#;`P$1``(1`0,1`?_$`+@```(#`0`#`0``````
M```````)!@<("@($!0,!`0`"`@(#`0`````````````&"`4'"0H!`P0"$```
M!@$#`P,#`08"!PD````!`@,$!08'`!$((1(3,10)02(5%E%A,D(C%Z$D<9&Q
M4K(S&5.S=-0UE=56.!$``@$#`@,&`04*#P$```````$"$0,$!08A$@<Q05%A
M$PAQ@9&Q(A31X4)28M(C<],)\*$R<H*BLD.35&1T%C87&?_:``P#`0`"$0,1
M`#\`Z[.1N6IM_:W]%BG3B/B80Y&T@F@?QJ2#\Y"KF,J<H@8S=-%4G8'38W=^
MW7`W[_?<KOW=?5#,Z&[1OY&%M?2;L+.3"TW">7E2C&XW.<>+LQA.VH1JJ2YV
M^TLCTSVAI^-I%O<&9"-S,OIR@WQ4(*JX+Q;3J_"A1D4QD7(%.JZ?F#IW%]PN
M8I!$=B[B!]@UH?IAT*U[68PS]?RLV4>#Y(W;O*O)TE5^?<3?/S\6RW&U"VOZ
M*^X6.TK4@#(KXIW@MQ6,W%0KA<1!4A"',!P`_P!I>Q0-A'U'IJZ^V^A$</3X
M9-KU_L[;B_TEQM2I6C^MV4::?BZ$0R-9L.\[,E#U*5[%V?,?:>TN40?JQOD>
M'.DF590_G6$I$0;D=*+#]^PIHI&$P[?0!U,=3Z"78Y4]-K?;C%2;<YTY5%3<
MG];LBJMM>!C[&OXLK*R*02;I2B[:\J7Q;*YEH=RD=7QNWA=M_O(NOV[;B4I_
MX]@`P_X:JMU#]O'JV[MW3;^78OIM\T+UVGQIS=A+,#5;4DN:$&GXI?</FU3(
M5JQS/(RL=(.S)D43!\S65%5O(LRG`56ZI%A,4HG)OV&]2&$!#TU6S974WJ[[
M7M_V=PZ/FY,L57(^O9G*4[.7CQE6=J<9U2<HU4)+C"34EQ2,IJNW]'W1ITL3
M)MPYVGRR2I*$J<))KP?:N]<!K=;FV]D@8J=:]$9-D@[*7K_3,H0/*EUZCXE0
M$N_UVUV8=@;OPM_;*TS>6GJF+J.%:OJ/'ZLIQ3G#CQ?)/FC7OI4J)J>#<TS4
M+V!=_EVKCC\:/@_E7$^WJ7GPAH!4OR4<S)WC^SIV/\:3)([($\[;6*5=)"DH
MJQK$>X4/[3^<4',H]023.4P`)FBAA#H(#H#<_&[,L5GK#5)R3&+I*+3$2BC-
MI)B7_*V!@`L9M'QEV%),)-NJ*8"`;IB`Z`O/0$%R'"7B>KQV6/KLC0K"#A-5
M*;<5V.LS<R)2J%4:K1TD()=BAC%-WE$#@)=O01T`E3E9RXYH<1[]'5"Q9'QY
M>6=@B'$Q"R#7'T?$*)MD%D$5"/6Q%%!*Y2.N`=#"0_40`/30&O\`C\'-S,>-
M:WDR>S]1:LTN$6G,P\)&8G@Y-PU8O"E7CSO7SAP1)0RS8X&,0I`,3?81$=]`
M5?R'SWS7X<)0URN\KC;->-Y26+%+2#2K'IKZ.>K)+N&S!VC'.%C%47;-E3$7
M`PI[I;"'7;0&V>+'*:B<J:(K;*DDXBY:'4:L[96'QR*/8&1<E7%(@K)@!'+-
MV+14R"H`'>0NX@&@-(R,BPB&+N3E'K6.CF""CIZ^>KIMFK5ND43*++KJF*FD
MF0H;B(B`:`4_D'Y*W]RR`7#W$/'BF6;:Y<JLR6J0]PC6B`D/C7D&C9,$ECQS
M8X@;W3@Z:`@(;EZAN!H&M88Y@6]D5]EODV-,>N4A.%>Q#4H%JE%&4$HBT5FY
M9JY-(&1`-@5*D41_V`?M9^.O)2.9NW6-.7=V5EQ,99M'Y$@*]-PXBF4PHM05
MCV+)VD10P[&,;OWZ;^F@,X<:.1/+-ERK'CMR>6B4BJU2<E(ART@(I@A,+QZC
M4C!Y&S#%(AI)L^!4_;_"8.W[BAN&@&Z:`-`**^1WG#8\"SM'QSBJ8:M;D*K>
MVVPYBD7!*%1=]D7$J;`8/'*KL7)'2?0X)=OIN&@&388RA!9FQA3<EUU7RQEK
MAFT@0HB7RH+B`IN4%R!U2536(/VB`#VB`_70%GZ`-`*5R^H0V;<@]W:'9/)D
M[C!_``QL?NIO^[?_``UU^NJ^U\;4_=YO?4,F*GRZQ%17?7[+C_>+;[4DX;%T
MY*O''K_7F6+C]@S>+-_#+-F+P1`I4)!N91JYW#82*JD`Q")*`.PE,&XA]>NK
MR])]MZ:U9^R7X6<OA]6Y%N$N"X.2X4[J->)#MPY5ZW&7/;E.SXQ=&O@GQKYH
MM-_;H>(F9"J0<4R7671:)3GF7%U%MGY#><@Q/;L8P"F<@F,;8`$1#Z:W#_S?
M0K.NY6TMMXUB[)*$<B4I<]B-U4E^@I2O!Q;;X)MQ[B+VM)S,C$MZKFW9QBG)
MVZ*DW%\/K^'%.GS]Y:J:3Y['N9*3;,A3?MD&CQPR3(B\3:)=H&(V`1$H&.C]
MH[_Q!TUN"WCY&5B7,S4;=IQO6XPN2@E&:@NZ/=QCP?B1:4[5J]&QCRG6$FXJ
M3K%R?C\I4.0("*;-TSIOF$;'F1!9@P;%4>O71-Q(9=XL0I2`L=0HEW$=B@4`
M^FM-=1-L:4\1<MVQCX#@W"W!.=R:[Y7)))<S=5QX*B5.!+-!U#*E<?-"=R^G
M24G2,4_"*\*?/4R#;O!VJ>,3]@`?L[@(!A$NYNO;T`.FN+?W#;-T[+T[)=M)
MSA!RBVES+AY<.W^%3=.@7;G-'F[6^(T[#H]V,Z</[8E/_O5=<R?MA@[703;%
MM]L=-BOFG,J[O3_M&9^N?T(LO6^2+D.R%>('&E'M5^LSM%E!5*$?S<@LNL1`
MIDV2!U$VQ%%!`@.'BX%12`?XE5"@'4=`)1I7'*=YD\?N1?)*]M5$\A9N</I/
M$`NFZ@2%9H=&E&I8")3:'`P)OIMC5BH@H3M`Z:^_\PZ`I+X>N23NH90MG&B\
M*JL!M"S]Y763Y0?-'72`*8DQ`%2.)2M2^R8NU5`]17)MZCH#I,T`:`YE/FXE
MC,,WXK2`X!WT":-MW`4?_4HP.OU'UT`[[@^X!QQ,P,Y$Y1*IC6K'$X&`2](=
MH!MS`.VY#`(#^P0'?0&(/ESSS08[![/#D/,QMER9>;/'$CJI"N4I699QS1N_
M!W)JM&(N5T5$W*J*1$S%*H?S"(!L4=`>U\2/&[*&':'=K[DZ-=5AQDQ2!<0-
M6?D%*5;Q<8E(E"0EVY_O:J/2N4SH)CL<"&'N`!Z:`ICYG>34[4(ZEX#J\DXC
M4+2V>V&\+-5S-EW$>T*@WC854Q#`96/D"OU%52CL`F1)^S0&BOB2P;$T7CTR
MRJ_8)*7/*BGY,9-0B9U4:J3=6#:,U1`5$4UT77<L`"`*&(01#[0T`U_0!H"N
M[)BJC6RYTW($W"I.;;01D0K$P4YD7+!.5,R.^1,9,0]PBN:/2^T^X!V]/4=`
M6)H"LLR95K6$\9W'*%M<$0A*A"/I=PF*A$UGJC1NHLC'LP.(>5Z\.GV)D#J8
MPZ`2DRXF6[D9P[S/R"N+$7&>,RR)\L5-%%%0'C6MUQL+ZNT]D@X**T:I,N/.
MFLF':40,3IH"-_#3R@,2:M7&:T/@(9RL^M-((NL!CA(MDA;V:+`RA@[$F[>-
M0,D0O\YC].N@.A[0!H!-F:9OV6>,DH]P%,6QI&()MMP`D7&F';?[=AW^NN`G
MJMKUC3/=EO>Q-\MQ:S"2?F\;'I]'9\Y<7:&#Z^P=-GVK[,_[<RX\8Y!*Q,T!
MS87I"BHGVQL3&,G+MR<Q@*"0.5FPD(8_IV[[C].NKR=(NH%JU8L^OGS7,XTL
MV;4)3DZTY5-QY4WV<O:0+<V@NYS^GCQK1_7G.2BO.B=7\>P]>\U.Y0MPDK-6
MHQ>;BI!-"5<LF*Z#R8KPG`$02G$43`1/SF1[R')N78_;MN4=0#=FT>H_3G?N
M9N+;N'D:MM#.FLAJPXW<G!YDHNWE6X-44G%SC<C5-34:)Q9]>CZKHNI:/:TW
M4;L;&;:K!2DG&W>IQK;;[:5HT^/"O8R35^T9)G&WL4H22CF9`2![)S"1V$='
M)K'!$CEXJMVF*B!_38H]PATUMO:W4#?FY["PL33,RQCJBN7<B$K-JTI/E4[D
MIT:C7LX<:41AM0TG;^!=]:=^U<NNO+"VU.<VN-(I=_T$RO5M1K\8RKI9N1C%
MV+$"E559L)**E?*<[DSEDZ2256!$ZZIB`(CL7MZ]=]3S>^Z;&@Z1;T:>9>Q[
MUFQVN%N[:NU;FY0FDY<O,W%=W#CWF'T72YY^3//]&W<A.?9S2A.%**DHMI5H
MD_.IA>\6=1=18QW!%S`"@%.`$(0W\1A\?80A1`=]Q#U^FN+GKWO.S=PLJ-ZX
MIRY)<M$N-5X)+MK\C^!O?;FF*'+RQ<5P\1NN$SBIBJDJ".XGADS?ZU5AUS$^
MV2?J=!]M3_&TY/YYS*H;W7+NO-BNZ\_H1:>M[D5$<?)-D2U<C<XXK^.G#TL1
MI*7-9.U9BFR`9W'P-?C6;JP,82?02$IFXJ)QS=\GW"`+=R:?\V@-2UKC;SBI
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MM`-`*#XR<@K/\=/,&?I7)6CL)M,\HG7;S(3D>G.SL0!7/CB;U3YZ3(N[78*`
MD)B&*<I5VJPGW`0`!`[,JO:*[=:]#6RIS+"P5JPQK27A)J+<$<L)*-?H$<M'
M;98G0R:R"A3!OL(;["`#TT!R\?/;1YFKY9Q=E4C5<]=MU<?UUW(IE7,U8RT(
M,:5BQ<J"`H(N7[=98Z)0$!4*D<>O;H!N?Q)9<K>5>%>-$81T@:0H+7]#6!@"
MI1=M'\(DFU*X<("/D11D`1.=$PAVJ%*(AOL.@&9:`-`?'GK#`U:+<S=EFHJO
MP[,O<ZE)I^UC(]N`[[>9V\510()MN@";<?IH#ZQ3%.4IR&`Q#E`Q3%$!*8I@
MW*8HAT$!`>@Z`1'S^M=HYE<G<??'QB.?;Q\5!(FR)FRPE2-(Q<>#%RB6/B))
M%,Z0#(09&ZJPM3'+Y_=%`?30&S(_`/.^*8LXV.YA45HPCVR#-FU1P5#D20;-
MDRI(I$*$H``4I"!H#FJY74++GQP\P*E=5YQG87IY*)R=`6.$B_T[!SQ@EG)I
M.MJ1R0J(LA4-%_YE`AA+XERCO]V@.QC"^4ZUFW%=&RK4'I)"OW:OLIEBY(7L
M`PJE%)TF)!$1(*#Q)0FP_P"[H"S]`))Y>UR>IN:K%.2#=5.,MSE&9AI`I#BS
M4(#=%HJT,OMX@=I&:=QB;[@4Y1^NNNM[XMD;PZ>^X[6-VY5JY'2-=O0R\:]%
M/TYQ].%J5ISI3U(NTW*-:J,HOO+L](]2T[6=DXV!8DGE8D7;N0_"3JY*5.WE
M?-1/Q3*4KF1W4.J59L[,@L`;>8HB"J?>(E$4#;;IG`/Y@V,7U#8=8'IIUNR=
M+N0I==G)A%JM:-57<WW^#7%=S3)1JNV;65%QG#FAX=S^/E_%XEX1&<UV4"XB
MFCTZ2LFZ*O)NBJF(JX12!,6S8RO=Y#$27()]]^HF$-6\T/W#K&T.6G8M^2R+
M\^>].M'**IR0YJU=))R\ZT(#F;&A=S8Y-R%86XTA&G!-UYG3S7#RH3>?Y)+N
MYR3>%=^:.DHY&+7:'5%0AFI8]-MY.W<2F7;+]RJ0]`!0`WU-]P>YE7M8R,F%
M[U-/OX\;4HN55R>DHM^<HRYI0_*2J87!Z=1MX=NUR\N1;N.:DE3CS-T^#5$_
M*IG^>RLL[;&8^],LS(J)D$5Q$_@W,`_T1ZBB!OYBA]HB(CMUWU5W?/7I?9)8
M,<CGQ:R<4W7E\H\:QKWKLJWPJV;`TW:4;=WUW"EUKBUW_'Q\N\KIHXEKE,L(
M&'07D926=)LV#-`AU%EW+@X))`!"[B!2G,`F'T*4-QU3S4\[<_5'<=C;F@V;
MV5J6;?C9LVH)N4YSE1<%V1JZMO@E5O@B8RM8>B84\_,E&WC6HN4Y/@DDJO[W
MBSH'QK7G%4H53K[PQC/(R$9(.^X-A(Z,D"KA+I_V*R@D_P!`:[-_1W:65L3I
M?H>T\YMYN%IUJ%RJI2XX\TX\/Q)2<:]]*E`=RZC;U;7\O4+*I9NWY./\VM$_
ME2J85Y9?);AWC8K?Z)$0&1\HYPJL4D9GCZCXZMLXV)+2L>U>PQIJR-XTL`QC
M"HR"*ZQ@<F4%/<A"BH(%ULHP8E?XM^65+QUFKD'G+F56\JTS-&;K*FVK]LF,
M8WN4KJ-67.R=MJV25:PKLL6I&.T0;H"J!-VJ9"]VW30'5U$RC*<BHR:C517C
MIB/92C!<R:B(K,I!LF[:JBDJ4BJ0J(+%'M,`&+OL(`.@.=3YH<]\><Z84L>$
MZ@SR+>>0V-[>UE*M$57%]W?M(F88O3P4\$S8TH4L8WC_`,,]=>/98Y55A3[0
M'<!T!A7XF.>N1.&#6SXJS]A7.;G#5@??G(>Q0F.K9-.Z%+F,7WH'A4F/F7@9
M'R+++^W(=8'!BF[1+W#H#I>1YZ\9U\(AR%+;IXF,AEOP0R"M#NJ<T67['2GL
M35@T&$^5;M9J>K?MW+MOU#0'*'\O6=G7-#.-'MN!,49OEZ74:4[@_P!12^+;
MC`)SCJ4<1SWW$='2$6C(E9H>V,0#JID\FX&*':.@'/\`QY_)1@ZG<>\(X.S%
M7\N8GR16(&#HGM+1BB]F@IEQ'$:0C*0C[(PA'<6"<D8I3B14Z9TN_8P!L.P%
MV?+'\>#+F'B=>[X\8M&/(''+%R]K#TOA:!<85-$3R%/EW`@7O%;Q)JM5C]QT
MC(>(FP*CH!'GQ<_(EG[B"O)8@S;AC.EQP<#]TV:$BZ#99*Q8QGT'B@2)&;1P
MS34>0ZJIU0<-DQ4.10B8)`!0-H#HI5MO$GY3,/WS%`(VR7A6/LS2[:QTFTT"
MWTB==MGJ<3,1A+3$,%FDPU2,N!3I@H`%$Q1]=`(TK'&SY&OB'S//WK"5,DN3
M/'.;6(2S1M9*J^=S5>:K'5;/)ZL,Q-(5NSPS<YBD>HD4;"*RA0[RFW`!QF(_
MF,X59&8(%N=OL.`[25,"RM3S94Y^G.8UX'_.:IS+F/-!R943=!507,3?]PAN
M!-;W\LG`^D1:T@US<QR(Y3)W)P>)X"QY%G'!Q`PII),*W%O!`ZAB[!W&*`#Z
MB&@$RY(Y(<KOD_Y.82Q-#\><JX]X9M,I5V3MGZAJ,FP4GX1@_(=U8;R^63!H
MBV9-NJ+(AA(4%%._N$>@#:.5WR@8HX\1N0:%CNIY(R[G&CI.(!I2ZKC:YR$"
MPL:+7M9$L%H3BDX9O&D4`O>**RASEW`@"(#L`J'XC^3V.L16/-]^Y6Q66ZMR
M!SI>62Q[-9,77=]"RL2F9V,<U:3;6$<(Q\A[B0.1<IQ("A`3'?[=`=5"*I%T
MDEDQ$4UDR*IB("41(H4#E$0$`$!$H^@]=`<P7S39^X^<F,3L*'B*.R3D3/F,
M+HU5B4ZSBR\JP\5&R3QFSMR4O9%()&.`1C6(^W3*H<3J>GKOH"EOB<^1.Y<3
M:5+8-Y+8;S@ABY*3<V&I7V)QI;[`K41=-FR$C"R\6UCU'P5\A6)%D#-DE!24
M46$X;"&@'\?]2GB-^._*?KFR>S_MQ_=3O_MMD#O_`$E^J/T=W^'].>7\O^=_
MI^PV]WX_ZG9X_NT!LBWTBI7Z(5@KC`Q]@BE=^YJ_2[^PP@`"=!8ADW#93H'W
M)G*;IZZA^]M@;,ZCZ+/;V^--Q=3T>?\`=WHUH_&$E2<)?E0E&7!<3*:1K>JZ
M#EK.T>_<Q\I?A1?;Y-.J:\FFC(<I\?>#'SH[AFZNL210XG]HUGDE6J6X[E*@
M5PQ453(3Z;G,/[]4OU7]VY[?,[+EDX,];PXRDWZ=O*A*$:]BASV9227G*3\S
M;6-U]WO9MJW>CAW9)4YI6FI/XTDD_F1Z!?CSPX0-B6&_%#??8)EI_P"0UZ[/
M[N3HWCKEM:IN-)_ZFW^Q/<^OV[I<7CX%?U<OSCR_Z>V'_P#[%?O_`'EI_P#'
MZ]DOW=71Z<>5ZKN.G^YM_L3Q_P"^[M_R^!_AR_./$OQXX8[RBI.WY0@&`3D"
M;:E$Q=]S%`_X\W8)@Z;[#MKX?_FKT+G<4LC/W#<CS)M/)M5?CQ=AT;7?1GZ?
MN`WC2D;&`G3A^CE^>:)Q?QZQ3B`3.*=6DTY4Y1(>=E%32<R)!*!#$3>+ALV*
M8N_=XBIB8!$!W#IJRG27VT='.BEQYFQM)MPUF4>5Y=]^OD\K5&HW)+ZB:KS>
MG&',FU*J=#7VY^H&ZMVKT]8R6\5.OI07);KV\8KMIW<S=.XNS6^B%D<MMMKM
M%KTG:[9*(0U?AT2N)*3<@H*#5$RA$2G4\1%#]HJ*%#T^N@(;B3,U&S?`OK1C
MUV_DZXTDUHI"9=1;R-9RJS8H>X7B3/4DCO622NZ?E*':)RB`>F@+-=NF[!JY
M?/%2-VC-NLZ=+J#LFBW;IF675./T(FF01']P:`@>.,L8\RY&/YG'5HCK3&Q<
MDO$/W4<<YB-I!L<Y%6Z@'(0P&W((ATV$.H:`L30!H`T`:`H:5Y*8DBLGPV&Q
MGW+_`")-OSQZ,!&14@].S4307<*+RCI-`&K!H0C<0%0Y^WN$`^N@+YT`:`-`
M1Z8J-3L*R;B?K%>G%T2"FBM,0L;)K)$$0$2)J/6RYR$$0#<`$`Z:`\(FFU"!
M7,Y@ZI6X9R;8#.(F#BXY<P``@`&59M45!V`P_7ZZ`DF@#0!H`T`:`-`&@#0!
MH`T`:`-`&@#0"R_DMSV^H6.H/"]+._<Y&S;(M:^V90:9G4\TK*KL"R;QFQ()
M3N_R8-U&($#U%4=]@ZZ`CW'S,^2,2Y<PAQ!E,*UZG52:QTZG&ZT=933%G@$V
M4=*R;B9N+-JV!E$OI^9:&_R9CB=(7)=SB(=N@-#<R^4DCQII`RD30%+C)29&
MS9D>66/&U95U)/R1:$/[LB#EQ,3C@ZO>6/;IG5,ANH;M3*8P`6AB^RQU4P5%
MY(O%0J^)17JJ=VN4/7V+1A'1JCEF$BX551:-VQE'ZQ%0$Q#E%;S'[!W-H#'D
MUSNOKG$%UY.5?'E=CL"T]^W:0/ZQEY!G><HMQGVL!(/Z['LF:S*';-3**K)%
M<'.LJ"0`)2@)A*!OECDAI*8FB\LQL/)/H^7HT5>VD(B=HE*'82L,VFTVHG=+
MMV:;A!JY^\3J%(':([Z`3A6^6/)J0A\^<VXDD`YPE3UT:]$XPMDY($36B6\V
MPB59.M*P#)]$JS:#DA4W"YW`I&$Z@D[@$!T`W_$V5&>3<.T_+:D>>#:66FQU
ML=QRBY7/XXKF*2DG:!'/8D#A%OW&`J@E()R@`B`;[:`3[@S*F0\W\F^0_(?&
ME`9716O-7-/I%@MDL>$Q[`4^,.LJA*+O&R#UXYLKMO$HE(W:HF[B**F.<O9U
M`8]PKY'SO)W$']P;'66%:DFT]+P:WX=\=_"2`Q;UPT,ZCG"Q2+;!X-U`$!*`
MF#M,8.N@/NVKDI'!+6ZOXSBV5S7Q^V<K9`N$E,HP.-J*NV`W=&3EF\3Q5W-&
M,F<#-&*#E5(4S`H!1#80(CPUS_D[DC4+-DNWTZ"J%,7FU(_'Z,4YD7LA,,68
MN`?2#I5^W9BHU,/A]NH5$@+`8P[!MH"@\K\^LD4KDK7,#UC"(6!>84[4H=U-
M*-KM)LW)@+&S*;%)NI%PD9(%(<R(NU@/L4WE!,0*!@-EX1LO(><-<BYYQK3Z
M&6/D&_Z-5IUO+:BSD<K[P70.T_"BLR49`DB!#'*0RWE'["]O4#%$U\@N1U>2
M\;@FE8*6GQ=QQW"D8XF/9VYD==0J:#RT(G2_%4YFP[#&=).E3.$"G`5"D^W<
M"#U3Y(<K6!7/:),6T-[&8@*H[4R$QMDHWQQ'LFQ7@KIR4J]BR24E(.A0_P`D
M@U;^5R9)4.TH%*)@-[\2<QW;/.$Z]DV]U!G3I*?<O#1K./7<KLI2#2*W]C.M
M@>)).$$GRIU2@0V^P);[]=`?A:.246:;M-8QFPCKB]H;==SD2W2DRG`XUQV#
M=-595O9K."#U5>2100.HJT8H.7"*?:8Y2@H3N`B'#?/N3^2-9L^2+;4*]4:,
MK.N(>@I1CJ1>/Y="-!/WLPJY?-VA744[%<H-U2))]QB'`0Z:`V;H`T`:`-`&
M@#0!H`T`:`6-=.,O(@_,JQ<BZZ3$UWA%JLRKN,F^09FP,U,5KC'LVLQ*)14;
M!R`3*CM?W9R(IKM^JX"*A1`1`#4>$>.;#&,]:,E6^QN\D9GOJA3VN^2;5)HD
MV9I@D#2LU.*(94L'68Q%!--)/O.JJ*?D4-W',&@,S<D^*_('/W)"@6TENH$1
MA7'**;ZO14LA*3,DWLRC,Y'-C<5@6Z45)3C-PY5*Q44=)(H%!-0Y51(*1P-2
M\C,(RF<N.-YPBG;G;":M%6C8A*WN$TT72\K$/(R33?OTX])!%$LN\BP!R""9
M2%(L?L)ML70&.W/#7,&6*QA7#V4WM&Q]@G#S"KN9FN4"5E)VQ91M==BT69WD
M@\?1$2S@J^^>"LNJ@/N55!,&X`/W%`D'R.9A6Q-@R!PGC$"-,B9FD83%]'BH
MT5".H2#6*9-S+(();J?C(]I&@U4VW$J:H]!VT!$HCA7EVSX0QGQ?M;BC8UPM
M42,760W%)F).Q6K*$HS4%TY;()OX2+CJ]"3,LH+MR)S+N.\A2E]1$`-F9NQ+
M;9OCO-X7P.]KU$D7%:BZ96W\LXE&T96J\R%FU4(V-&-)!ZLLG$-1;IE$-C=^
MYC?M`S-6>-'(/&E%C>.>*'N)J?A=6C0L-8,C)_GSY04M+EHV_7,\UBDD$H=X
M>7>%7*W!55/L26$QC;E`A@-.HX._MEQT?X6X_+,J?(QU17A*E+20"H4DPL@1
M)>;F%6Z!C+OY`X'475*GN*IQ,`!H!85BX(\U)KC%6,%L,AXEK3=E8RN[7"0#
MBT-R7IH]!=29FKM:EVRCZ6DG;D"&4;)H`BJ90QC&$2$T`UO`F,)O$&+8*B2,
MW'R[F%8D:QS6,CTXVOP#-%`J;*"B0*B60>1\?V]@.70F=+E`#'`#;[@9_P".
M7$^R4/,V9.0V9Y>KV[*&1IU8E5-`?D7<;0Z7[ARX3@HUU+L8]UY'0JI>0/$(
M)^`.TYNX=`;0LX6,U>F2U`(@;0:.<A`_GE7:,+^3%,0:C)JL$'+Q-F"@AWBD
MF<^WH`Z`6#6N#>:L?X(R0QJ%ZHC[E1FZ4<*9,S+/KV(C=G#28+ED&-3=-H=Q
M*(NFY'!_"J+=OY1$!4#[2[`1_+WQ[7U3$V$^/^$).C1V,X.>-9<V.K2YFF4O
MD.>1!AX))Z:(;K*N4SB5QW)`<A=C!L!1$=P&!O\`'60(?`$YCFFW5`V10H\G
M"5:WO(QG"QL;/JQIVT4Z3C(1NF1C&L'':8"E!138!$3"(]`%8S?`_F?+<6XC
M`C'(6**PBC.>ZLT;77-A9'OA79FX2DU<K6>.7=NG3I%(""U1;=ARD_J'5`2E
M(`UOC]B^6P]C"`H<O-L)96'1(FU:PL8E$UVOM`;H)E@Z\UV.^-%MUTU%2J.U
M5G!U%CB8W;VE*!=>@#0!H`T`:`-`&@#0!H`T`:`-`&@#0"C^9'_[TX3_`/A[
A'_QR6@&X:`-`&@#0!H`T`:`-`&@#0!H`T`:`-`&@/__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
